Jump to content

Idalopirdine: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Dr
Rescuing 2 sources and tagging 0 as dead.) #IABot (v2.0.9.3
 
(33 intermediate revisions by 25 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
⚫
| verifiedrevid = 428858963
| Watchedfields = changed
| IUPAC_name =
⚫
| verifiedrevid = 451553711
⚫
| image =
| IUPAC_name = 2-(6-Fluoro-1''H''-indol-3-yl)-''N''-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
⚫
| image = Lu-AE58054.svg


<!--Clinical data-->
<!--Clinical data-->
| tradename =
| tradename =
| pregnancy_category =
| pregnancy_category =
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number =
| CAS_number = 467459-31-0
| ATC_prefix = None
| ATC_prefix = None
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem = 21071390
| ChEMBL = 3286580
| synonyms = Lu-AE-58054
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 19878969
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10710
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 59WCJ0YNWM
| smiles = FC(F)C(F)(F)COc1cccc(c1)CNCCc3c[nH]c2cc(F)ccc23
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YBAWYTYNMZWMMJ-UHFFFAOYSA-N


<!--Chemical data-->
<!--Chemical data-->
| C=20 | H=19 | F=5 | N=2 | O=1
| chemical_formula =

| molecular_weight =
| smiles =
}}
}}


'''Lu AE58054''' is a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[5-HT6 receptor|5-HT<sub>6</sub> receptor]] [[receptor antagonist|antagonist]] under development by [[Lundbeck]] as an [[augmentation (psychiatry)|augmentation therapy]] for the treatment of [[cognitive deficit]]s associated with [[Alzheimer's disease]] and [[schizophrenia]].<ref name="urlU.S. Development Programs. - Lundbeck">{{cite web | url = http://www.lundbeckinc.com/usa/pipeline/default.asp | title = U.S. Development Programs. - Lundbeck | format = | work = | accessdate = }}</ref><ref name="urlSearch of: Lu AE58054 - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=Lu+AE58054 | title = Search of: Lu AE58054 - List Results - ClinicalTrials.gov | format = | work = | accessdate = }}</ref> As of February 2010 it is in [[Clinical trial#Phase II|phase II clinical trials]].<ref name="urlSearch of: Lu AE58054 - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=Lu+AE58054 | title = Search of: Lu AE58054 - List Results - ClinicalTrials.gov | format = | work = | accessdate = }}</ref>
'''Idalopirdine''' ([[International Nonproprietary Name|INN]]) (code names '''Lu AE58054''',) is a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[5-HT6 receptor|5-HT<sub>6</sub> receptor]] [[receptor antagonist|antagonist]] under development by [[Lundbeck]] as an [[augmentation (psychiatry)|augmentation therapy]] for the treatment of [[cognitive deficit]]s associated with [[Alzheimer's disease]] and [[schizophrenia]].<ref name="urlU.S. Development Programs. - Lundbeck">{{cite web | url = http://www.lundbeckinc.com/usa/pipeline/default.asp | title = U.S. Development Programs. | work = Lundbeck }}</ref><ref name="urlSearch of: Lu AE58054 - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=Lu+AE58054 | title = Search of: Lu AE58054 - List Results | work = ClinicalTrials.gov | publisher = National Library of Medicine, U.S. Department of Health and Human Services }}</ref> As of October 2013 it is in [[Clinical trial#Phase III|phase III clinical trials]].<ref name="urlSearch of: Lu AE58054 - List Results - ClinicalTrials.gov"/>


A phase III trial of two different daily doses of Lu AE58054 on top of 10&nbsp;mg of [[donepezil]] for mild-to-moderate Alzheimer's failed to meet its [[primary endpoint]] with either dose.<ref name=Taylor-fb>{{cite web | vauthors = Taylor NP | date = 23 September 2016 | url = http://www.fiercebiotech.com/biotech/phiii-alzheimer-s-flop-takes-chunk-out-lundbeck-hits-axovant-aftershocks | title = PhIII Alzheimer's flop takes chunk out of Lundbeck, hits Axovant with aftershocks }}</ref> Two further phase III trials failed too, the company confirmed in early 2017.<ref name=Taylor-fb/>
⚫
== References ==
⚫
{{Reflist}}


== External links ==
==See also==
* [[Cerlapirdine]]
⚫
* [http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1272757_EN.asp Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia]
* [[Latrepirdine]]
⚫
* [http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1357623_EN.asp Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease]


⚫
==References==
⚫
{{Reflist}}

==External links==
⚫
* [http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1272757_EN.asp Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia] {{Webarchive|url=https://web.archive.org/web/20110709031205/http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1272757_EN.asp |date=2011-07-09 }}
⚫
* [http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1357623_EN.asp Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease] {{Webarchive|url=https://web.archive.org/web/20100204055707/http://lundbeck.com/investor/releases/ReleaseDetails/Release_1357623_EN.asp |date=2010-02-04 }}


{{Antidementia}}
{{Antidementia}}

{{Nootropics}}
{{Serotonergics}}
{{Serotonergics}}
{{Tryptamines}}


[[Category:5-HT6 antagonists]]
[[Category:5-HT6 antagonists]]
[[Category:Antidementia agents]]
[[Category:Antidementia agents]]
[[Category:Nootropics]]
[[Category:Nootropics]]
[[Category:Tryptamines]]
[[Category:Organofluorides]]
[[Category:Fluoroarenes]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"